Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 6/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15413092 | 0.79 | FGFR4 (0.45) | FGFR4GRM5 | |
| SCHEMBL15412865 | 0.72 | FGFR1 (0.43) | FGFR4GAAMAPT | |
| SCHEMBL15434004 | 0.70 | FGFR4 (0.62) | FGFR4GRM5ALDH1A1 | |
| SCHEMBL674040 | 0.67 | ALDH1A1 (0.65) | GAAMAPTGRM5APPALDH1A1 | |
| SCHEMBL16140275 | 0.62 | ALDH1A1 (0.50) | MAPTGRM5APPALDH1A1 | |
| SCHEMBL673820 | 0.62 | APP (0.69) | APPALDH1A1 | |
| SCHEMBL29724128 | 0.61 | GRM5 (0.52) | GRM5HTT | |
| SCHEMBL28074286 | 0.61 | APP (0.52) | GRM5APPALDH1A1 | |
| SCHEMBL29829307 | 0.60 | ALDH1A1 (0.38) | FGFR4GRM5APPALDH1A1 | |
| SCHEMBL29829575 | 0.60 | GRM5 (0.51) | FGFR4MAPTGRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109627239-B | Inhibitors of fibroblast growth factor receptors | 缆图药品公司 | 2021-10-12 | — | — | CN | disclosed |
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180362613-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2018-12-20 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-9340514-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-9126951-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150210694-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2872491-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | Blueprint Medicines Corporation (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210694-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885CSF1R 105/4885GAA 559/4885 |
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885CSF1R 105/4885GAA 559/4885 |
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885CSF1R 105/4885GAA 559/4885 |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885CSF1R 105/4885GAA 559/4885 |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885CSF1R 105/4885GAA 559/4885 |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885CSF1R 105/4885GAA 559/4885 |
| US-20180362613-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885CSF1R 105/4885GAA 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.